IRCT20230724058910N1
Not yet recruiting
Phase 4
To Study the effect of Empagliflozin on the cardiovascular biomarkers Galectin-3 and sST-2 in type 2 diabetic patients myocardial infarction with requiring primary angioplasty
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Condition 1: Myocardial Infarction. Condition 2: Type 2 diabetes.
- Sponsor
- Zanjan University of Medical Sciences
- Enrollment
- 60
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Type 2 diabetic patients (Hb A1C: 6\.5\-8\)
- •Diabetes treated with oral agents
- •Typical chest pain during the 12 hours before presentation lasting more than 30 minutes
- •ST\- segment elevation above 0\.1 mV in two leads or more in ECG
Exclusion Criteria
- •Cardiogenic shock
- •Diabetic ketoacidosis
- •History of CABG
- •Type 1 diabetic patients
- •Severe liver failure
- •End stages cancer or history of any cancer
- •History of severe allergy to empagliflozin or its formulation components
- •Severe renal failure (eGFR \<30 mL/minute/1\.73 m2\), end\-stage renal disease (ESRD), or dialysis
- •Hypovolemia
- •Any inflammatory disease under treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Efficacy of Empagliflozin on cardiac function in non- diabetic patients after primary percutaneous angioplasty on left anterior descending coronary arteryacute myocardial infarction.121-09IRCT20200727048226N1Tehran University of Medical Sciences88
Active, not recruiting
Phase 1
Impact of Empagliflozin on heart in patients with myocardial infarctioMyocardial infarctionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-004591-22-ATMedical University of Graz/Department of Internal Medicine/Division of Endocrinology and Diabetology476
Active, not recruiting
Phase 1
Effect of Empagliflozin and Semaglutide on the Cardiovascular system and Kidneys in patients with type 2 diabetes – A randomized TrialType 2 Diabetes MellitusMedDRA version: 20.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2019-000781-38-DKAarhus University Hospital120
Not yet recruiting
Phase 3
Effect of Empagliflozin on clinical and echocardiographic parameters in patient with reduced LVEF heart failureIRCT20210809052117N1Shahid Beheshti University of Medical Sciences44
Unknown
Phase 4
Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 DiabetesDiabetesCardiovascular DiseaseNCT02998970Unity Health Toronto97